Evotec announced that one of its co-owned pipeline assets, Second Genome's SGM-1019, discovered based on microbiome science and in development for nonalcoholic steatohepatitis ("NASH"), has entered Phase II development, triggering a $2m milestone payment to Evotec. NASH represents a large and rapidly growing market opportunity and has been an active area of pharma R&D and consolidation in the past few years. Similarly, a dysfunctional microbiome - the collection of microorganisms that live in th ....
25 Jan 2019
Partnered asset for NASH moves into Phase II
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Partnered asset for NASH moves into Phase II
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
25 Jan 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Evotec announced that one of its co-owned pipeline assets, Second Genome's SGM-1019, discovered based on microbiome science and in development for nonalcoholic steatohepatitis ("NASH"), has entered Phase II development, triggering a $2m milestone payment to Evotec. NASH represents a large and rapidly growing market opportunity and has been an active area of pharma R&D and consolidation in the past few years. Similarly, a dysfunctional microbiome - the collection of microorganisms that live in th ....